Labcorp offers a comprehensive, biomarker-driven approach to renal disease research, enabling earlier detection, more precise patient stratification and streamlined global trial execution.
Identify and validate novel renal biomarkers (e.g., NGAL, KIM-1, suPAR) for early detection and disease monitoring.
Streamline your clinical trial logistics with our global central lab network while gaining access to consistent, high-quality data from more than 70 clinical trials involving more than 33,000 participants from 60 countries.
Use Labcorp’s lab data to identify high-prevalence populations, optimize site selection, and ensure inclusive enrollment.
Labcorp offers a robust portfolio of traditional, early-stage, inflammatory, immunological and fibrotic biomarkers to support renal drug development across all phases.
| Group | Biomarkers |
|---|---|
| Traditional and diagnostic biomarkers | Creatinine, eGFR, BUN, UACR, UPCR, Microalbumin, albumin, total protein, creatine kinase |
| Early-stage renal damage | Cystatin C, uEGF-1, MCP-1, KIM-1, NGAL, clusterin, osteopontin, GDF-15, β2-microglobulin, renin, angiotensin II |
| Inflammation markers | TNF-α, IL-6, TGF-β1, suPAR, EGF |
| Immunological markers | IgA, IgG, IgM, Gd-IgA1, C3, C4, soluble C5b-9, cytokine panels including TNF-α and IL-1β |
| Fibrosis markers | PRO-C3, PRO-C6, PROC-6/Cr, PRO-C3/Cr, LG1M, C3M, C3M/Cr |
Enhance your drug development programs with Labcorp’s comprehensive solutions and insights across various therapeutic areas.
Let’s discuss your program to find out how we can help accelerate your renal disease clinical trials.
